Related Experiment Video
Updated: Dec 10, 2025
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
741
Weight Loss as an Effective Strategy to Decrease Opioid Use and Frequency of Vaso-Occlusive Crises in Patients with
1Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
Journal of Palliative Medicine
|September 4, 2020
Summary
Weight loss through lifestyle changes and bariatric surgery effectively reduced opioid use and vaso-occlusive crises in a sickle cell disease patient. This non-opioid approach improved quality of life by decreasing pain and hospitalizations.
Area of Science:
- Hematology
- Metabolic Disorders
- Surgical Innovation
Background:
- Sickle cell disease (SCD) management often involves opioid analgesics for vaso-occlusive crises (VOCs).
- Opioid use carries significant risks, including addiction, depression, and respiratory depression.
- Alternative, non-opioid pain management strategies are crucial for improving patient outcomes.
Observation:
- A patient with SCD and morbid obesity (BMI 42 kg/m²) experienced frequent VOCs requiring high opioid doses (870 MME/day).
- Historical data suggested a correlation between lower BMI (<25 kg/m²) and absence of VOC hospitalizations.
- This observation prompted a recommendation for weight loss.
Findings:
- The patient underwent a multidisciplinary weight loss program and laparoscopic sleeve gastrectomy.
- Achieved a 30 kg weight loss, reducing BMI to 29 kg/m².
- Decreased daily opioid requirement by 58% (to 365 MME/day) and experienced no further VOC hospitalizations.
Implications:
- Weight loss interventions, including bariatric surgery, show promise as non-opioid adjunctive therapies for SCD pain management.
- Reducing opioid reliance in SCD patients can mitigate associated risks and improve quality of life.
- This case highlights the potential of multidisciplinary programs and surgical weight loss in managing complex SCD complications.
More Related Videos
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
20.1K
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
1.8K
Related Concept Videos
01:21Drug Dosing: Obese Patients
127
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
127
01:26Atherosclerosis III: Management
226
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
226
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
138
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
138
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
96
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
96
01:18Chronic Kidney Disease IV: Nursing Management
193
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
193
01:22Heart Failure VI: Adjunct Therapies
149
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
149